Skip to main content

Moderna slows coronavirus vaccine trial enrollment to ensure minority representation, CEO says

Minorities, the elderly and people with underlying health conditions are at highest risk of Covid-19, and are being prioritized for enrollment in large vaccine trials. Moderna's CEO said the company is slowing enrollment in its trial to ensure the Black community is represented.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.